• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2025, Vol. 42 ›› Issue (3): 222-226.

• 药品评价 • 上一篇    下一篇

喜炎平注射液联合无创呼吸机通气对伴有Ⅱ型呼吸衰竭慢性阻塞性肺疾病患者肺功能及血清炎症介质水平的影响

李旭东, 李清贤, 姚凤佳   

  1. 郑州市第三人民医院呼吸与危重症医学科, 河南 郑州 450000
  • 收稿日期:2025-01-26 修回日期:2025-03-07 接受日期:2025-08-05 出版日期:2025-06-28 发布日期:2025-08-05

Effect of Xiyanping Injection Combined with Non-invasive Ventilator Ventilation on Pulmonary Function and Serum Inflammatory Mediator Levels in Patients with Chronic Obstructive Pulmonary Disease Accompanied by Type Ⅱ Respiratory Failure

   LI Xudong, LI Qingxian, YAO Fengjia   

  1. Department of Respiratory and Critical Care Medicine, Zhengzhou Third People′s Hospital, Henan Zhengzhou 450000, China
  • Received:2025-01-26 Revised:2025-03-07 Accepted:2025-08-05 Online:2025-06-28 Published:2025-08-05

摘要:  目的:探讨喜炎平注射液联合无创呼吸机通气对伴有Ⅱ型呼吸衰竭慢性阻塞性肺疾病(COPD)患者肺功能及血清炎症介质水平的影响。方法:选取我院2021年8月至2024年10月收治的伴有Ⅱ型呼吸衰竭COPD患者150例,根据随机数字表法分为两组,各75例。对照组采用常规治疗+无创呼吸机通气治疗,观察组在对照组基础上增加喜炎平注射液治疗。比较两组临床疗效、肺功能[第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、呼气峰值流速(PEF)]、血气分析指标[动脉血二氧化碳分压(PaCO2)、动脉血氧分压(PaO2)、动脉血氧饱和度(SaO2)、pH值]、血清炎症介质水平[白细胞计数(WBC)、降钙素原(PCT)、可溶性髓系细胞触发受体-1(sTREM-1)、C反应蛋白(CRP)]及不良反应发生情况。结果:观察组总有效率92.00%高于对照组78.67%(P<0.05);组间不良反应比较无明显差异(P>0.05);治疗后观察组的FEV1、FVC、PEF均高于对照组(P<0.05);两组治疗后的PaCO2均降低,PaO2、SaO2、pH值均上升,其中观察组改善幅度更大(P<0.05);与对照组比较,观察组治疗后的WBC、PCT、sTREM-1、CRP更低(P<0.05)。结论:喜炎平注射液联合无创呼吸机通气治疗伴有Ⅱ型呼吸衰竭COPD患者的效果明显,不仅可有效改善肺功能及血气分析指标,还可减轻炎症反应,且具有安全性。

关键词: font-size:medium, ">慢性阻塞性肺疾病;呼吸衰竭;喜炎平注射液;无创呼吸机通气;肺功能;炎症

Abstract: Objective: To investigate the effect of Xiyanping injection combined with noninvasive ventilator ventilation on pulmonary function and serum inflammatory mediator levels in patients with chronic obstructive pulmonary disease (COPD) accompanied by type Ⅱ respiratory failure. Methods: A total of 150 COPD patients accompanied by type Ⅱ respiratory failure admitted to our hospital from August 2021 to October 2024 were selected. Patients were divided into two groups according to a random number table method. Each group has 75 cases. The control group received conventional treatment plus non-invasive ventilator ventilation, while the observation group received Xiyanping injection in addition to the control group. The clinical efficacy, pulmonary function [forced expiratory volume in one second (FEV1), forced vital capacity (FVC), peak expiratory flow rate (PEF)], blood gas analysis indicators [arterial partial pressure of carbon dioxide (PaCO2), arterial partial pressure of oxygen (PaO2), arterial oxygen saturation (SaO2), pH value], serum inflammatory mediator levels [white blood cell count (WBC), procalcitonin (PCT), soluble myeloid cell triggering receptor-1 (sTREM-1), C-reactive protein (CRP)], and adverse reactions were compared between the two groups. Results: The total effective rate of the observation group was 92.00%, which was higher than that of the control group (78.67%) (P<0.05). There was no significant difference in adverse reactions between the groups (P>0.05). After treatment, the FEV1, FVC, and PEF in the observation group were all higher than those in the control group (P<0.05). After treatment, PaCO2 in both groups was decreased, while PaO2, SaO2, and pH were increased. The improvement was more significant in the observation group (P<0.05). Compared with the control group, the WBC, PCT, sTREM-1, and CRP levels in the observation group were lower after treatment (P<0.05). Conclusion: The effect of Xiyanping injection combined with non-invasive ventilator ventilation in the treatment of COPD patients accompanied by type Ⅱ respiratory failure is significant. It can not only effectively improve lung function and blood gas analysis indicators, but also reduce inflammatory reactions and is safe.

Key words: font-size:medium, ">Chronic obstructive pulmonary disease; Respiratory failure; Xiyanping injection; Non-invasive ventilator ventilation; Pulmonary function; Inflammation

中图分类号: